SSY Pharmaceutical Research Institute SSY Pharmaceutical Research Institute

Corporate email

中文/EN

简体中文

English

NEWS CENTER

Group Announcement

Media reports

Group News

Moxifloxacin Hydrochloride Sodium Injection Approved for Production

Category:

Group Announcement

Time：2018-11-19

On October 15, the Institute of Pharmaceutical Research once again reached a moment of triumph: after five years of development, it obtained the first-ever drug registration approval in China for moxifloxacin hydrochloride sodium chloride injection packaged in non-PVC soft bags. The product, branded as Yixinrui, was developed entirely in-house by the company, and both the formulation and its raw materials have also been approved simultaneously.
On October 15, the Institute of Pharmaceutical Research once again reached a moment of harvest: after five years of effort, we have obtained our... The first batch of registration approvals in China for non-PVC soft-bag packaged moxifloxacin hydrochloride sodium injection, marketed under the trade name Yixin. Rui, and both the formulation and the raw materials used are independently developed by the company and have been approved together.
Moxifloxacin is a fourth-generation quinolone with broad-spectrum and antibacterial activity, featuring an 8-methyl group. Oxide-based fluoroquinolone antibacterial agents. The market has broad prospects.
 

Keywords:

Previous

Chairman Qu Jiguang has been named on the provincial list of “40 Prominent Private Entrepreneurs Honoring 40 Years of Reform and Opening-up.”

The company has ranked among the top 100 private enterprises and the top 100 manufacturing private enterprises in the province.

Next

Previous:

Chairman Qu Jiguang has been named on the provincial list of “40 Prominent Private Entrepreneurs Honoring 40 Years of Reform and Opening-up.”

Next:

The company has ranked among the top 100 private enterprises and the top 100 manufacturing private enterprises in the province.